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A 37-year-old man, auto mechanic by trade, presented 
with multiple facial skin lesions, accompanied by burning 
sensation and pain, eye redness, fever and fatigue. The 
symptoms occurred 4 days before admission. Two weeks 
earlier he was consulted dermatologically due to hand ec-
zema treated subsequently with topical steroids; addition-
ally, he reported presence of concomitant facial erythema 
with scaling. Besides, the personal and familial medical 
history was unremarkable. Clinical examination revealed 
multiple skin erosions covered with serosanguineous 
crust, disseminated on his face, hands and forearms (Fig. 1); 
 increased body temperature of 38.7 degrees Celsius, 
and conjunctival congestion. Laboratory tests revealed 
increased level of inflammatory parameters (C-reactive 
protein 21.25 mg/L, leukocytosis 13.48 ×109/L).
Which diagnosis is most likely in our patient?
A. Impetigo
B. Primary varicella infection
C. Kaposi’s varicelliform eruption
D. Ecthyma
E. Pemphigus vulgaris
Figure 1. Clinical presentation: multiple, disseminated facial 
skin erosions covered with serosanguineous crust
See next page for answer.
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Answer: KAposi’s vAricelliform eruption, 
eczemA herpeticum
Eczema herpeticum (EH), formerly known as Kaposi’s 
varicelliform eruption, arises mostly as a secondary viral 
infection in patients with underlying skin disintegrity di-
sorders. It was first described by Moritz Kaposi in the 19th 
century. EH is a rare condition, that responds well to antiviral 
therapy, but if disregarded, it can assume a fulminant course. 
The pathogenesis of EH remains unclear. It is considered 
that impaired skin barrier function, observed in several 
chronic skin diseases, can lead to increased susceptibility to 
disseminated viral infection [1]. Aside from skin disintegrity 
impairment, higher risk of EH is also associated with cellular 
and humoral immunity deficiencies. According to recent 
reports, high total serum IgE level, low levels of cathelicidin, 
as well as reduced activity of natural killer cells can contri-
bute to widespread dissemination of viral infection [2–4]. 
Furthermore, increased concentration of interleukin 4, the 
cytokine responsible for suppressing the production of T 
helper cells and IFN-γ, also comprises risk factor of EH [5].
The role of immune response defects in pathogenesis of EH 
still remains a subject of investigation. EH occurs most often 
as a superimposition of Herpes simplex virus-1 infection on 
atopic dermatitis. Other viruses that may be involved in pa-
thogenesis are Herpes simplex virus-2, Coxsackie A16 virus 
and Varicella-zoster virus. The infection is transmitted via 
direct contact or develops as a reactivation of the latent 
virus [6]. 
Apart from atopic dermatitis, EH has been described in 
patients with psoriasis, pityriasis rubra pilaris, Darier’s dise-
ase, Grover’s disease, Hailey-Hailey disease, autoimmune 
bullous dermatoses, as well as irritant and allergic contact 
dermatitis [7]. Furthermore, there have been reported cases 
of EH in patients with cutaneous T-cell lymphoma [8], or in 
immunocompromised patients, who had undergone laser 
resurfacing [9].
As atopic dermatitis typically reveals in childhood, the 
vast amount of patients suffering from EH is comprised 
of pediatric population. Immunocompromised patients 
are also particularly vulnerable to disseminated viral in-
fection [6].
The clinical manifestation of EH includes an eruption 
of multiple painful clusters of monomorphic umbilicated 
vesiculopustular lesions, most commonly reported on the 
head, neck or upper trunk. The initial exanthema alternates 
into punched out ulcers covered by hematic crusts. At a later 
stage lesions can evolve to coalescing erosions with scallo-
ped border [10]. Skin eruption is often associated with fever 
and lymphadenopathy. Most often, skin lesions subside in 
2–6 weeks, without scarring [6].
In case of more severe course of the disease, infection 
can disseminate to the brain, liver, lungs or to the gastroin-
testinal tract. The mortality of HSV encephalitis, which is lo-
calised mainly in the temporal lobe, reaches up to 70% [11]. 
Involvement of periocular region can be also associated 
with severe complications — patients, who suffer from 
herpes keratitis that occurred in the course of the disease 
are vulnerable to blindness [12]. Furthermore, erosions may 
become secondary infected with bacteria, most commonly 
Staphylococcus aureus, thus leading to bacteremia and 
septic shock. 
The diagnosis is based mainly on clinical presenta-
tion. In case of  atypical clinical course, the Tzanck smear 
or skin biopsy should be performed. Direct fluorescence 
antigen testing, another diagnostic technique, allows 
the precise determination of infectious agent. PCR, aside 
from its highest specificity and sensitivity in diagnostic 
approach, can be used to detect viral DNA in cerebro-
spinal fluid [10]. 
The main purposes of  EH treatment are both termina-
tion of viral infection and alleviation of symptoms of the 
underlying disease. Antiviral therapy should be initiated as 
soon as possible. In less-severe disease in adults acyclovir 
400 mg 5 times daily for 5 to 10 days is recommended; for 
pediatric patients acyclovir 25 mg/kg/day is administered 
in 5 equal doses for 5 to 10 days. In case of severe course 
of the disease, in immunocompromised patients in severe 
dysphagia intravenous infusion (dosing at 15 mg/kg per day) 
is recommended for at least 5 days. It is compulsory to 
adjust the dosage of the drug in patients with renal in-
sufficiency and to recommend proper hydratation in pa-
tients treated with intravenous acyclovir, due to the risk 
of drug precipitation as crystals in the kidneys. In case of 
periocular involvement, ophthalmological care is man-
datory. In the case of suspected bacterial superinfection 
systemic antibiotic therapy should be recommended [6]. 
In our patient — immunocompetent and with no history of 
atopic dermatitis — EH development was a consequence 
of disruption of epidermal barrier in the course of contact 
dermatitis, most probably due to occupational exposure. 
Immediate therapy with acyclovir combined with systemic 
antibiotics led to gradual resolution of skin eruption. Al-
though EH is not a rare its development in patients with 
contact dermatitis has been previously described in only 
a few cases [13–15]. 
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